In comparison, in a phase 2 study of the anti-VEGF antibody bevacizumab plus carboplatin/paclitaxel in patients with locally advanced or metastatic NSCLC the patient incidence rate of thrombotic events was 17.6% in the 15-mg/kg cohort (grade 3/4, n = 5) [27]. Here, VEGFA is linked to non-small cell lung carcinoma.